ProCE Banner Activity

Key COVID-19 Studies Influencing My Practice Following IDWeek 2022—Dr Huhn and Dr Mussini

Conference Coverage
Multimedia

Listen to expert insights on updates and new COVID-19 data from IDWeek 2022, including data on vaccines, risk factors and risk stratification, diagnostics, therapeutics, treatment of patients with immunocompromise, and long COVID.

Released: November 08, 2022

Share

Faculty

Gregory Huhn

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Cristina Mussini

Cristina Mussini, MD

Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Gregory Huhn, MD, MPHTM

Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Gregory Huhn, MD, MPHTM: consultant/advisor/speaker: Gilead Sciences, Integritas, Janssen, Lilly, Merck, ViiV; researcher: Gilead Sciences, Janssen, Lilly, ViiV.

Cristina Mussini, MD

Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy

Cristina Mussini, MD: consultant/advisor/speaker: AbbVie, Angelini, Gilead Sciences, GlaxoSmithKline, Janssen, MSD, Pfizer, Roche, ViiV; researcher: Gilead Sciences, Janssen, MSD, ViiV.